Formulation and Stability for Biologics: A Practical Guide

Every drug has a shelf life, and every shelf life is a claim you have to defend. For a small molecule tablet, that defence is often a well-worn path. For a monoclonal antibody, a fusion protein or an enzyme, it is a moving target. Proteins unfold, clump, oxidize and fall apart in ways that depend on pH, temperature, light, the container, and even trace enzymes left over from the cell line. Formulation and stability work is where you decide how the molecule survives the trip from fill line to patient, and where you build the data that proves it.

Why Formulation and Stability Go Together

Formulation is the set of choices around the active ingredient: buffer, pH, tonicity agents, stabilizers, surfactants, concentration, and whether the product is a liquid or a lyophilized cake. Stability is the evidence that those choices work over time. The two cannot be separated.

The core rules are well established. ICH Q1A(R2), issued in final form in November 2003, sets the storage conditions and data packages for new drug substances and products. It asks for at least three primary batches and, in the general case, 12 months of long-term data at submission (FDA, 2003). ICH Q5C adapts these principles for biotechnological products and adds expectations specific to proteins. A 2025 draft ICH Q1 runs to 108 pages, roughly five times the length of the original Q1A (RAPS, 2025). Thin-needle subcutaneous products generally need viscosity below about 20 cP (Mijangos et al., 2025).

How Biologics Degrade

Small molecules usually degrade by a handful of chemical reactions such as hydrolysis, oxidation and photolysis. Proteins add a layer of physical instability on top of that. The main pathways are:

• Aggregation. Partially unfolded molecules stick together, forming soluble oligomers, sub-visible particles and visible particles. Aggregates can reduce potency and are a recognized immunogenicity concern.
• Deamidation and isomerization. Asparagine residues convert to aspartate or isoaspartate, and aspartate can isomerize. When this happens in a complementarity-determining region, binding can change.
• Oxidation. Methionine and tryptophan are the usual targets. Triggers include light, peroxides from excipients, trace metals and headspace oxygen.
• Fragmentation. Peptide bonds break, often in the hinge region of antibodies, producing clipped species that show up on CE-SDS.

Which pathway dominates depends on the molecule, the formulation and the stress. That is why the first job of a stability program is to characterize the degradation profile, not just to watch numbers on a chart.

Excipients and the Polysorbate Problem

A typical biologic formulation is simple on paper. A buffer such as histidine, acetate or citrate holds the pH. A sugar such as sucrose or trehalose stabilizes the native structure and, in lyophilized products, protects the protein during drying. An amino acid or salt adjusts tonicity or viscosity. A surfactant, almost always polysorbate 20 or 80, protects the protein at air-liquid and solid-liquid interfaces.

Polysorbates are also the most common source of late surprises. Trace host cell proteins, often at ppm or sub-ppm levels, include lipases and esterases that cleave polysorbate ester bonds and release free fatty acids. Those fatty acids can exceed their solubility and form sub-visible or visible particles. In an industry survey cited in a 2025 review, about 65% of companies had seen polysorbate content fall in liquid vial products (Felix et al., 2025). Mitigations include cell lines with key enzymes knocked out, tighter control of polysorbate raw material, and chelators. Oxidative polysorbate degradation is a separate pathway and needs its own controls.

“A stable formulation is not one where nothing changes. It is one where you know what changes, how fast, and why it still meets specification.”

High-Concentration Subcutaneous Formulations

The push to move antibodies from intravenous infusion to subcutaneous injection has made high-concentration formulation a core skill. Hand-held subcutaneous injections are limited to volumes under about 3 mL, so a large dose has to be packed into a small volume. A 2025 review defines high-concentration formulations as 100–200 mg/mL and notes that viscosity should stay below about 20 cP for self-administration through a thin needle (Mijangos et al., 2025).

Concentration brings molecules closer together, which raises self-association and aggregation risk. Salts and amino acids such as arginine hydrochloride are the main viscosity-reducing tools, but some of them can reduce conformational stability. Another option is co-formulation with recombinant human hyaluronidase, which temporarily increases tissue permeability so that larger volumes can be given. Each choice changes the stability profile.

Lyophilization vs Liquid

Liquid formulations are easier to use. There is no reconstitution step, and they fit prefilled syringes and autoinjectors. Many antibodies are marketed as liquids where stability allows. Lyophilization removes water by freezing and sublimation, which slows many degradation pathways and can ease cold-chain demands. The trade-off is longer production timelines and specialized equipment (Pharma’s Almanac, 2026). Lyophilization also adds its own stability questions: residual moisture, cake appearance, reconstitution time, and the in-use stability of the reconstituted solution.

Factor	Liquid	Lyophilized
Ease of use	Ready to inject	Needs reconstitution
Device fit	Prefilled syringe, autoinjector	Mostly vials, dual-chamber systems
Degradation rate	Higher in solution	Slower in the dry state
Manufacturing	Simpler fill-finish	Longer cycle, specialized dryers
Extra tests	Particles, polysorbate content	Moisture, cake, reconstitution time

Building a Stability Program That Holds Up

For a refrigerated product under ICH Q1A(R2), long-term storage is 5°C ± 3°C, with accelerated studies at 25°C/60% RH for six months. If significant change appears early at accelerated conditions, shelf life rests on real-time data (FDA, 2003). ICH Q5C is firmer still for biologics: storage periods should always be based on long-term, real-time, real-condition studies. For claims over six months, the initial submission needs at least six months of data on at least three batches of final container product (ICH Q5C).

Forced Degradation, Accelerated and Real-Time

• Forced degradation. Heat, light, oxidation, pH extremes, agitation and freeze-thaw push the molecule beyond normal conditions. The goal is to map pathways and prove that your methods are stability-indicating.
• Accelerated studies. Moderately elevated temperature gives early trend data, supports excursion assessments and informs development choices.
• Real-time studies. Storage at the labelled condition is the basis for the shelf-life claim and must continue through the full proposed period.
• In-use studies. Dilution into infusion bags, reconstitution and multidose use each need data that match the label instructions.

Container Closure

The container is part of the formulation. ICH Q5C asks for liquid products to be tested inverted or horizontal as well as upright, so that the stopper is in contact with the product, and for data on every marketed container closure combination. In August 2026, FDA issued a draft guidance to replace its 1999 container closure guidance, stressing extractables and leachables assessment, protection from oxygen, moisture and light, and shipping studies (RAPS, 2026). Silicone oil in prefilled syringes is a well-known aggregation trigger.

What This Means for Biotech and CDMO Teams

Stability failures usually come from programs designed to tick boxes rather than answer questions. A few principles hold up across molecules and phases:

• Start with forced degradation. Know your pathways before you lock analytical methods or excipients.
• Test the surfactant, not just the protein. Track polysorbate content and particles over time, and link them to host cell protein clearance.
• Treat the device as formulation. Run stability in the final container, in every orientation that matters.
• Plan for the label you want. In-use, excursion and shipping data take months to generate. Build them into the protocol early.

Small molecule teams face the same logic with fewer pathways, and the same consolidated guideline will apply to them. For biologics, early formulation choices often set the limits of the whole commercial program. Our earlier pieces on compendial method verification and cell line development, where host cell protein profiles are set, cover related ground.

Terraforme Biosciences helps developers design stability protocols, interpret ICH Q1A(R2), Q5C and the draft ICH Q1, and build CMC sections that stand up to review. Learn more about our regulatory guidance services.